| Literature DB >> 28509303 |
Akira Iguchi1, Atsushi Eino2, Hajime Yamazaki2, Tomoyuki Ito2, Takako Saeki2, Yumi Ito3, Naohumi Imai4, Yutaka Ohsawa3, Hiroyasu In5, Kimiyoshi Ichida6, Ichiei Narita3.
Abstract
Familial juvenile hyperuricemic nephropathy (FJHN) is an autosomal-dominant disorder that is characterized by hyperuricemia and chronic renal failure and results in end-stage renal failure. FJHN is caused by mutations in the UMOD gene, which encodes uromodulin. Uromodulin contains three epidermal growth factor (EGF)-like domains, a domain of eight cysteine residues (D8C), and a zona pellucid-like domain. Over 90 % of UMOD mutations are missense mutations, and over 80 % exist in exon 4, which encodes both D8C and the EGF-like domains. A 56-year-old woman was diagnosed with hyperuricemia with a serum uric acid level of 7.5 mg/dL, and stage III chronic kidney disease (CKD) with a serum creatinine level of 1.12 mg/dL and an estimated glomerular filtration rate of 39.9 mL/(min 1.73 m2). The patient had a family history of hyperuricemia and stage IV CKD; both the patient and her affected family members had a novel mutation in the UMOD gene: c.C518G (p.P173R), located between the EGF-like domains and D8C. This mutation, along with previously reported nearby mutations, causes a clinically mild phenotype of FJHN. It is important that physicians consider the diagnosis of FJHN in patients with a family history of hyperuricemia associated with renal dysfunction, even if the patient has only mild renal impairment.Entities:
Keywords: FJHN; Hyperuricemia; Mutation; UMOD; Uromodulin
Year: 2013 PMID: 28509303 PMCID: PMC5413657 DOI: 10.1007/s13730-013-0069-y
Source DB: PubMed Journal: CEN Case Rep ISSN: 2192-4449